Skip to main content
. 2022 Jan 12;17(1):e0262169. doi: 10.1371/journal.pone.0262169

Fig 2. Four-month follow-up levels of anti-nucleocapsid IgG are associated to disease severity and to COVID-19 symptoms.

Fig 2

A) Four-month follow-up levels of anti-nucleocapsid IgG were significantly higher in convalescent patients compared to HCW. B) In addition, four-month follow-up levels were significantly increased in HCW with self-reported fever, ageusia, malaise, cough, anosmia, dyspnea, abdominal symptoms, or headache prior to study inclusion. Crossbars depict the median. P-values are shown with brackets. Sx; symptoms. AU: Arbitrary Units.